Form 4 for BIIB Biogen
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001127602-24-012405 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-03 | 2024-04-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +240 | 9,751 | +3% | $0 |
| D | 2024-04-03 | 2024-04-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $214.83 | -117 | 9,634 | -1% | -$25.1K |
| D | 2024-04-03 | 2024-04-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -240 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-01 | M | A | 240 | $0.00 | 9,751.37 | D | — | — | (F1) 1. Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/28/2024. |
| 2 | Common | Common Stock | 2024-04-01 | F | D | 117 | $214.83 | 9,634.37 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2024-04-01 | M | D | 240 | $0.00 | 0 | D | $0.00 · — to 2024-04-01 | 240 Common Stock | (F2) This award was granted to the reporting person on April 1, 2021. The final portion of the awards vested on the third anniversary of the grant date. |